• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Pharmaceutics >Liposomal and Ethosomal Gels for the Topical Delivery of Anthralin: Preparation Comparative Evaluation and Clinical Assessment in Psoriatic Patients
【2h】

Liposomal and Ethosomal Gels for the Topical Delivery of Anthralin: Preparation Comparative Evaluation and Clinical Assessment in Psoriatic Patients

机译：蒽环素局部给药的脂质体和气凝胶凝胶剂：银屑病患者的制备比较评价和临床评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To enhance anthralin efficacy against psoriasis and reduce its notorious side effects, it was loaded into various liposomal and ethosomal preparations. The nanocarriers were characterized for drug encapsulation efficiency, size, morphology and compatibility between various components. Optimum formulations were dispersed in various gel bases and drug release kinetics were studied. Clinical efficacy and safety of liposomal and ethosomal Pluronic F-127 gels were evaluated in patients having psoriasis (clinicaltrials.gov identifier is ). Safety was assessed by recording various adverse events. Drug encapsulation efficiency ≥97.2% and ≥77% were obtained for liposomes and ethosomes, respectively. Particle sizes of 116 to 199 nm and 146 to 381 nm were observed for liposomes and ethosomes, respectively. Fourier-Transform infrared (FT-IR) spectroscopy and differential scanning calorimetry (DSC) studies confirmed the absence of interaction between anthralin and various nanocarrier components. Tested gel bases showed excellent ability to sustain drug release. At baseline, the patients had a median Psoriasis Area and Severity Index (PASI) of 3.4 for liposomes and 3.6 for ethosomes without significant difference. After treatment, mean PASI change was −68.66% and −81.84% for liposomes and ethosomes, respectively with a significant difference in favor of ethosomes. No adverse effects were detected in both groups. Anthralin ethosomes could be considered as a potential treatment of psoriasis.
机译：为了增强蒽醌类抗牛皮癣的功效并减少其臭名昭著的副作用，将其装入了各种脂质体和溶酶体制剂中。表征了纳米载体的药物包封效率，大小，形态和各种组分之间的相容性。最佳配方分散在各种凝胶基质中，并研究了药物释放动力学。在患有牛皮癣的患者中评估了脂质体和内体Pluronic F-127凝胶的临床疗效和安全性（clinicaltrials.gov标识符为）。通过记录各种不良事件来评估安全性。脂质体和脂质体的药物包封效率分别为≥97.2％和≥77％。对于脂质体和脂质体，分别观察到116至199nm和146至381nm的粒径。傅里叶变换红外（FT-IR）光谱和差示扫描量热法（DSC）研究证实了蒽林与各种纳米载体组分之间不存在相互作用。经测试的凝胶基质显示出优异的维持药物释放的能力。在基线时，患者的脂质体中位数银屑病面积和严重程度指数（PASI）为3.4，而对于脂质体为3.6，无显着差异。治疗后，脂质体和脂质体的平均PASI变化分别为-68.66％和-81.84％，其中对脂质体的有利差异显着。两组均未发现不良反应。 Anthralin质体可能被认为是牛皮癣的潜在治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号